Absolute Bioavailability, Safety, Tolerability, and Pharmacodynamics Following Subcutaneous (SC) Injection of 100 mg BI 765080 Relative to Intravenous (IV) Dose in Healthy Male Subjects
Latest Information Update: 15 Aug 2024
At a glance
- Drugs BI 765080 (Primary) ; BI 765080
- Indications Unspecified
- Focus Pharmacokinetics
- Sponsors Boehringer Ingelheim
- 23 Mar 2022 Status changed from active, no longer recruiting to completed.
- 21 Jan 2022 Status changed from recruiting to active, no longer recruiting.
- 30 Nov 2021 Planned End Date changed from 18 Jan 2022 to 10 Mar 2022.